Literature DB >> 5646032

Epinephrine maculopathy.

A E Kolker, B Becker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5646032     DOI: 10.1001/archopht.1968.03850040554010

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


× No keyword cloud information.
  15 in total

Review 1.  The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery.

Authors:  A J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  1998

Review 2.  Efficacy and adverse effects of medications used in the treatment of glaucoma.

Authors:  C B Camras; C B Toris; R R Tamesis
Journal:  Drugs Aging       Date:  1999-11       Impact factor: 3.923

Review 3.  Pharmacological therapy for glaucoma: a review.

Authors:  P F Hoyng; L M van Beek
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 4.  Vitreous anatomy and the vitreomacular correlation.

Authors:  Shoji Kishi
Journal:  Jpn J Ophthalmol       Date:  2016-05-10       Impact factor: 2.447

5.  Federov iris-supported intraocular acrylic lens.

Authors:  P Jardine; J H Sandford-Smith
Journal:  Br J Ophthalmol       Date:  1974-08       Impact factor: 4.638

Review 6.  A risk-benefit assessment of drugs used in the management of glaucoma.

Authors:  T Taniguchi; Y Kitazawa
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

7.  Cystoid macular edema of nonretinal vascular origin.

Authors:  B E Wright
Journal:  Bull N Y Acad Med       Date:  1982-09

Review 8.  A long-term follow-up study of cystoid macular edema in aphakic and pseudophakic eyes.

Authors:  C P Wilkinson
Journal:  Trans Am Ophthalmol Soc       Date:  1981

9.  Epinephrine distribution after topical administration to phakic and aphakic eyes.

Authors:  S G Kramer
Journal:  Trans Am Ophthalmol Soc       Date:  1980

10.  Cystoid macular edema associated with limbal melanoma.

Authors:  J R Wolter
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.